
Let’s start with a bit of background on the country. In this 728 Years old country, the city of Basel is situated on the Rhine River in northwest Switzerland, close to the country’s borders with France and Germany. The city is the third most populous city in a country of more than 8.3 Million Inhabitants (± 1 Mio. Foreigners). Switzerland has a GDP (in Billions USD) 659.80, an annual GDP Growth 1% and a GDP/Capita 78'259 (USD). Health Expenditure (% of GDP) stands at 11% and Health Expenditure/Capita 8'608 (USD).
AxonLab, Werfen’s longtime partner in Switzerland, has more than 30 years of experience in the IVD and medical software market, with a direct presence in nine European countries and more than 350 employees and exceeding 100 Million euros of turnover in 2018.
Universitätspital Basel is a large hospital with more than 1’000 beds, 7’250 employees from 88 Nations, including 54 Clinics and providing services yearly for more than 2’800 births, 38’000 inpatients, and more 1 Mio outpatients.
The laboratory of the hospital employs 160 employees and performs 4 Mio analysis per year across several specialties, Clinical Chemistry, Hematology, Immunology and Microbiology. The relationship in Hemostasis with this customer started as a foot in the door approach with the installation of Rotem Delta in the Laboratory managed by the responsible of the Hemostasis practice, Prof. Tsakiris.
This initial collaboration built the foundation for further collaboration with Prof. Tsakiris and when the time came for a new solution for the Coagulation Laboratory a long process of discussion started to find the best solution that fit the needs of the Laboratory.

This started an international series of events going as far back as July 2017 in Berlin, where the ISTH was taking place. During the ISTH, Prof. Tsakiris was able to see first-hand a demonstration of the HemoCell solution and the value it can deliver to a laboratory by providing quality results through the standardization of all sample processing steps, the reduction of the risk of human error and possible exposure of operators to biohazards. By also improving the efficiency of the laboratory by reducing the average sample turnaround time (TAT), maximizing the lab throughput and optimizing lab resources while at the same time having a minimal footprint and optimizing the utilization of analyzers, reagents and consumables.

This was followed by a speaking engagement during our annual Advanced Hemostasis Seminar that was taking place in Athens in October of 2017. Through this engagement, we were able to communicate the commitment of the company to be a reference in Hemostasis, supporting clinicians and laboratorians in spreading the latest advancements in Hemostasis and build new generations of experts in the specialty.
A joint effort of AxonLab and the EEMEAI Team was made to present a customized solution to the customer in November of 2017 at the hospital in Basel to communicate how the HemoCell solution provided significant value and provided the right solution to the problems identified with the customer.
This process of collaboration and support was continuous to assist the customer in championing the value of HemoCell to internal stakeholders by qualifying and quantifying the impact of this unique solution internally.
Another step in the journey of the HemoCell took place in March of 2018 in Barcelona, where a small delegation from the customer visited Val d’Hebron accompanied by representatives from both AxonLab and Werfen EEMEAI.
Several configurations of the HemoCell later, a site inspection and qualification, and less than a year later in 2019, the order finally came and the time to plan and install started. The plan involved 6 months from the placement of the order until the customer was ready to go live.
The installation involved several of complexity, 3 companies (Werfen, Thermofisher and AxonLab), several functions (Sales, Logistics, Service, IT, and Support) and departments (Werfen EEMEAI, IL WW Service, Werfen Clinical Software, Thermofisher Service, AxonLab Service, Sales and Marketing) in addition to the logistical requirements of the customer.
This involved a great effort of planning, coordination, and effort that involved 14 People working on the project, traveling from 5 different cities to Basel for the installation, more than 6 different Hotel used and a total of 62 Hotel nights booked during more than 11 weeks from the site inspection to Go-Live to install the following Thermofisher Components in addition to the ACL TOP 750 LAS named Donald and Daisy.

Once the hardware is operational, a core component of the value HemoCell is delivered through the different features of HemoHub.
With HemoHub as the middleware of the overall solution we can maximize the efficiency and throughput of sample routing of the overall solution. In addition, this allows the customer to Centralize access to information from the different instruments, and proactively notify users about each instrument’s status and test feasibility, centralize quality control management, key performance indicators & statistics, reporting tools to support accreditation and compliance as well as testing standardization, hemostasis sample validation and sample bank traceability to simplify the laboratory workflow.
The configuration of HemoHub was also a team effort where the collaboration of Clinical Software, the LIS provider, AxonLab Team, Werfen EEMEAI, IL WW Service and of course the customer.
Eleven weeks later, HemoCell was ready to go Live and able to run patient samples. A ribbon cutting ceremony was organized and celebrated with a lot of enthusiasm by all the parties involved.
![]() |
![]() |
Congratulations to everyone involved in the successful installation of the first HemoCell in the EEMEAI World.

Elias El Bouchi (Marketing Manager Hemostasis) & Valeria De Luca (Key Account Manager Hemo Lab)

